Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
复制标题
DOI：
10.1056/nejmoa1300874
复制
发表时间：
2013-07-11
影响因子：
158.5
通讯作者：
Platzbecker, U.
中科院分区：
文献类型：
--
作者：
Lo-Coco, F.;Avvisati, G.;Platzbecker, U.
背景全反式维A酸（ATRA）联合化疗是急性早幼粒细胞白血病（APL）的标准治疗方法，治愈率超过80%。使用三氧化二砷联合或不联合 ATRA 治疗的初步研究显示出高效且降低了血液学毒性。 方法我们进行了一项 3 期、多中心试验，比较 ATRA 加化疗与 ATRA 加三氧化二砷治疗被归类为低至中度风险的 APL 患者（白细胞计数、
BACKGROUNDAll-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity.METHODSWe conducted a phase 3, multicenter trial comparing ATRA plus chemotherapy with ATRA plus arsenic trioxide in patients with APL classified as low-to-intermediate risk (white-cell count,